Mind Medicine Inc (MNMD)

Currency in USD
9.850
-0.140(-1.40%)
Closed·
After Hours
9.830-0.020(-0.20%)
·
MNMD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MNMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.67010.140
52 wk Range
4.70010.436
Key Statistics
Prev. Close
9.85
Open
10.02
Day's Range
9.67-10.14
52 wk Range
4.7-10.436
Volume
1.18M
Average Volume (3m)
1.24M
1-Year Change
42.55%
Book Value / Share
2.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MNMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.000
Upside
+153.81%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

Mind Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Mind Medicine Inc Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Mind Medicine Inc SWOT Analysis


Breakthrough Therapy
MindMed's MM120, an LSD-based compound, shows promise in treating Generalized Anxiety Disorder with rapid onset and lasting effects
Market Potential
Analysts project peak U.S. sales of $1.6 billion for MM120, with potential revenue reaching $2.29 billion by 2031 in the multi-billion-dollar GAD market
Regulatory Landscape
FDA's Breakthrough Therapy Designation for MM120 could expedite development, reducing regulatory risks and attracting investor interest
Financial Outlook
Analyst price targets range from $16 to $55, reflecting significant upside potential despite current unprofitability in this clinical-stage company
Read full SWOT analysis

Mind Medicine Inc Earnings Call Summary for Q2/2025

  • MindMed reported Q2 2025 EPS of -$0.50, missing forecasts by 35.14%, but stock rose 2.99% in aftermarket trading
  • Strong cash position of $237.9M ensures operational stability until 2027; R&D expenses increased to $29.8M from $14.6M in 2024
  • Three pivotal Phase III trials underway for GAD and MDD; FDA Breakthrough Therapy Designation received
  • CEO highlights potential of MM120 ODT as 'best in class treatment'; top-line data readouts expected in 2026
  • Analysts maintain strong buy consensus with 1.4/5 rating; company exploring additional pipeline expansion opportunities
Last Updated: 01/08/2025, 09:32
Read Full Transcript

Compare MNMD to Peers and Sector

Metrics to compare
MNMD
Peers
Sector
Relationship
P/E Ratio
−6.5x−0.9x−0.5x
PEG Ratio
−0.220.000.00
Price/Book
4.0x2.5x2.6x
Price / LTM Sales
-1.8x3.3x
Upside (Analyst Target)
108.1%230.5%43.3%
Fair Value Upside
Unlock4.7%6.9%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.000
(+153.81% Upside)

Earnings

Latest Release
Jul 31, 2025
EPS / Forecast
-0.50 / -0.37
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MNMD Income Statement

People Also Watch

51.43
BMNR
+24.59%
4.130
ATAI
-0.48%
16.900
QBTS
-1.57%
39.350
SMR
-11.93%
159.03
CRCL
+3.99%

FAQ

What Stock Exchange Does Mind Medicine Trade On?

Mind Medicine is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Mind Medicine?

The stock symbol for Mind Medicine is "MNMD."

What Is the Mind Medicine Market Cap?

As of today, Mind Medicine market cap is 749.47M.

What Is Mind Medicine's Earnings Per Share (TTM)?

The Mind Medicine EPS (TTM) is -1.38.

When Is the Next Mind Medicine Earnings Date?

Mind Medicine will release its next earnings report on 11 Nov 2025.

From a Technical Analysis Perspective, Is MNMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Mind Medicine Stock Split?

Mind Medicine has split 1 times.

How Many Employees Does Mind Medicine Have?

Mind Medicine has 74 employees.

What is the current trading status of Mind Medicine (MNMD)?

As of 11 Aug 2025, Mind Medicine (MNMD) is trading at a price of 9.85, with a previous close of 9.85. The stock has fluctuated within a day range of 9.67 to 10.14, while its 52-week range spans from 4.70 to 10.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.